Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Imane Nafia"'
Autor:
Jean-Philippe Guegan, Florent Peyraud, Christophe Rey, Oren Ngouala, Ophélie Odin, Imane Nafia, Isabelle Soubeyran, Sylvestre Le Moulec, Alban Bessede, Antoine Italiano
Publikováno v:
Cancer Research. 83:4341-4341
Background: Immune checkpoint inhibitors (ICI) has revolutionized the management of patients with non-small cell lung cancer (NSCLC). However, most patients with advanced NSCLC patients displayed primary resistance to ICI. Indoleamine 2,3-dioxygenase
Autor:
Assia Chaibi, Coriolan Lebreton, Dominique Bodet, Jean-Philippe Guegan, Guillaume Babin, Antoine Italiano, Alban Bessede, Imane Nafia
Publikováno v:
Cancer Research. 83:4705-4705
Background: It’s now increasingly recognized that ovarian cancer (OC) ascites play a significant role in OC progression - behavior of tumor cells is influenced by the nature of their surrounding microenvironment. Thus, characterization of ascites c
Autor:
Imane Nafia, Assia Chaibi, Christophe Rey, Jean-Philippe Guegan, Alban Bessede, Coriolan Lebreton, Antoine Italiano
Publikováno v:
Cancer Research. 82:2527-2527
Background: Tumor microenvironment (TME) of epithelial ovarian cancer is unique among solid tumors as tumor cells create their "malignant ascites" TME. These ascites, acting as a complex mixture of soluble factors and cell components, are known to be
Autor:
Jean-Philippe Guegan, Florent Peyraud, Aurelien Marabelle, Nathalie Chaput, Dominique Bodet, Laure Fontan, Anthony Gaultier, Imane NAFIA, Francois-Xavier Danlos, David Planchard, Caroline Robert, Caroline Even, Mohamed Khettab, Lambros Tselikas, Luc Friboulet, Jean-Charles Soria, Fabrice Andre, Fabrice Barlesi, Alban Bessede, Antoine Italiano
Publikováno v:
Cancer Research. 82:1251-1251
Background: The discovery of immune checkpoint blockers (ICB) has revolutionized the systemic approach of the treatment of cancer. However, most patients receiving ICB do not derive benefit. Therefore, there is a crucial need to identify reliable pre
Autor:
Imane Nafia, Jean-Philippe Guegan, Assia Chaibi, Noëlie Bos, Doriane Bortolotto, Christophe Rey, Loïc Cerf, Florent Peyraud, Antoine Italiano, Alban Bessede
Publikováno v:
Cancer Research. 82:622-622
Background: Soft Tissue Sarcoma (STS) is known to be resistant to cancer immunotherapy including the prototypical immune checkpoint inhibitor (ICI) anti-PD1 (1). It’s therefore crucial to develop innovative strategies aiming at improving current cl
Autor:
Alban Bessede, Aurelien Marabelle, Jean-Philippe Guegan, Florent Peyraud, François-Xavier Danlos, Sophie Cousin, Nathalie Chaput, Mariella Spalato, Guilhem Roubaud, Mathilde Cabart, Mohamed Khettab, Assia Chaibi, Christophe Rey, Imane Nafia, François-Xavier Mahon, Jean-Charles Soria, Antoine Italiano
Publikováno v:
Journal of Clinical Oncology. 40:12000-12000
12000 Background: Pain is the most common symptom experienced by patients with advanced cancer. Acetaminophen (APAP, commonly known as paracetamol) alone or in combination with a weak opioid, such as codeine or tramadol, is usually considered as the
Autor:
Anne-Laure Blayo, Gaël Hommet, Alban Bessede, Célia Halter, Marjorie Sidhoum, Imane Nafia, Laurène Deshons, Alexia Dumont, Ludovic Herbin, Stephan Schann, Xavier Leroy, Stanislas Mayer, Christel Franchet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Elevated levels of Prostaglandin E2 (PGE2), an eicosanoid notably synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the tumor microenvironment. COX-2-positive solid tumors have the ability to use this p
Autor:
Imane Nafia, Maud Toulmonde, Doriane Bortolotto, Assia Chaibi, Dominique Bodet, Christophe Rey, Valerie Velasco, Claire B. Larmonier, Loïc Cerf, Julien Adam, François Le Loarer, Ariel Savina, Alban Bessede, Antoine Italiano
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology
Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP
Publikováno v:
Cancer Research. 80:3938-3938
Background: While antiangiogenic therapies have been shown effective in preclinical and clinical trials, tumors can acquire resistance conferring them the ability to survive and grow under hypoxic conditions, even, induced by antiangiogenic drugs the
Autor:
Christel Franchet, Anne-Laure Blayo, Gaël Hommet, Marjorie Sidhoum, Stanislas Mayer, Alexia Dumont, Ludovic Herbin, Xavier Leroy, Alban Bessede, Stephan Schann, Laurène Deshons, Imane Nafia, Célia Halter
Publikováno v:
Cancer Research. 80:6697-6697
Elevated levels of Prostaglandin E2 (PGE2), an eicosanoid notably synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the tumor microenvironment. COX-2-positive solid tumors have the ability to use this pathway as a